Julius Kalcevich Joins Corporate Leadership Team as Chief Financial Officer; Michael Graham Repositioned as Chief Commerical Officer

WINNIPEG, Manitoba – TheNewswire - July 17, 2023 - Cytophage Technologies Inc., a Canadian biotechnology company that produces bacteriophages, (the “Company”) today announced the appointment of Julius Kalcevich as Chief Financial Officer. He takes over the role from Michael Graham, who moves into the newly created position of Chief Commercial Officer.  

Mr. Kalcevich is an experienced finance and investment banking professional with an extensive background in corporate finance, strategy development and financial management. Most recently, Mr. Kalcevich held the position of CFO of iAnthus Capital Holdings, Inc., which owns and operates licensed cannabis cultivation, processing, and dispensary facilities throughout the United States.  As a founding team member of iAnthus, Mr. Kalcevich helped grow the company from a staff of 10 people to an organization with over 1000 personnel and revenue of $200 million.    Previously, Mr. Kalcevich was a partner with BG Partners Corp., a Toronto based merchant bank focused on early stage and venture financings.  Prior to this, he was a director in the investment banking groups of CIBC World Markets and Dundee Capital Markets where he assisted in the completion of over 40 transactions representing over $5 billion of transaction volume. Mr. Kalcevich earned a B.A. in Economics at McGill University and an MBA at Columbia University.

Michael Graham has extensive experience in capital markets supporting growth companies. He has been CFO with Cytophage since 2017, raising more than $15M.  Prior to this, Mr. Graham was the CFO of RHC Capital, a Canadian listed public issuer, where he aided in restructuring and executing a qualifying transaction.

"The Cytophage management team welcomes the addition of Julius Kalcevich as Chief Financial Officer, and the repositioning of Michael Graham as Chief Commercial Officer " said Dr. Steven Theriault, founder and CEO of Cytophage Technologies Inc. " In preparation for our go-public qualifying transaction with Cuspis Capital III Ltd, Cytophage will benefit from Julius’ extensive experience in leading financial operations and capital formation.  Michael will transition seamlessly to Chief Commercial Officer, where he will now be able to focus his time and resources on the commercial development of Cytophage’s products.” Mr. Kalcevich’s and Mr. Graham's appointments are effective immediately. Both individuals will be based in Toronto, while the Company’s scientific staff continues to be Winnipeg-based.  

About Cytophage

Cytophage is a leading-edge Canadian biotechnology company that uses advanced molecular genetic techniques and synthetic biology to create highly effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security.   Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria, Cytophage generates customized phages to address specific bacterial infections, including strains resistant to antibiotics.  Cytophage has also recently developed a ‘phage-display’ methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.  

For further information on the proposed transaction between Cytophage and Cuspis Capital III, please see:   Cuspis Capital III Ltd. and Cytophage Technologies Inc. Enter into Letter of Intent for Qualifying Transaction (thenewswire.com).  

For more information on Cytophage, please visit www.cytophage.com.

Contact:

Heather Medwick, President

heather@cytophage.com

431 388 8873